NTRA Natera, Inc.

Nasdaq Services-Medical Laboratories DE CIK: 0001604821
AI RATING
HOLD
55% Confidence

Investment Thesis

Natera demonstrates robust 36% revenue growth with positive free cash flow ($18M) and a fortress balance sheet ($1.1B cash, 0.16x D/E), but operates at significant losses with -13.4% operating margin and -12.2% net margin, indicating structural profitability challenges at scale. The company has sufficient liquidity to sustain operations, but path to profitability remains unclear and requires material operational improvement.

Strengths

  • + Strong revenue growth of 35.9% YoY demonstrates market demand and customer acquisition momentum
  • + Positive free cash flow of $18M and operating cash flow of $40.2M despite net losses indicates operational cash generation capability
  • + Fortress balance sheet with $1.1B cash reserves, very low leverage (0.16x D/E), and strong liquidity ratios (2.96x current, 2.83x quick)

Risks

  • ! Severe profitability deficit: -$93.5M operating loss on $696.6M revenue with negative operating and net margins despite scale
  • ! Razor-thin free cash flow margins at 2.6% with minimal profitability headroom relative to revenue base
  • ! Gross profit anomaly ($723.5M exceeds revenue of $696.6M) suggests accounting complexity or data quality issues requiring clarification
  • ! High insider activity (43 Form 4 filings in 90 days) warrants investigation for potential insider confidence concerns

Key Metrics to Watch

Financial Metrics

Revenue
696.6M
Net Income
-85.1M
EPS (Diluted)
$-0.60
Free Cash Flow
18.0M
Total Assets
2.6B
Cash
1.1B

Profitability Ratios

Gross Margin 103.9%
Operating Margin -13.4%
Net Margin -12.2%
ROE -4.8%
ROA -3.3%
FCF Margin 2.6%

Balance Sheet & Liquidity

Current Ratio
2.96x
Quick Ratio
2.83x
Debt/Equity
0.16x
Debt/Assets
32.1%
Interest Coverage
-22.98x
Long-term Debt
282.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-09T12:08:23.821364 | Data as of: 2026-03-31 | Powered by Claude AI